These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Biochemical substrates of mental disturbances in Parkinson's disease. Agid Y; Ruberg M; Dubois B; Javoy-Agid F Adv Neurol; 1984; 40():211-8. PubMed ID: 6695597 [No Abstract] [Full Text] [Related]
4. [The probenecid test. Evaluation in clinical medicine of cerebral metabolism of serotonin and dopamine]. Véron JP; Mérienne L Nouv Presse Med; 1972 Feb; 1(8):537-9. PubMed ID: 4258943 [No Abstract] [Full Text] [Related]
5. Imaging the addicted brain: from molecules to behavior. Volkow ND J Nucl Med; 2004 Nov; 45(11):13N-16N, 19N-20N, 22N passim. PubMed ID: 15584131 [No Abstract] [Full Text] [Related]
6. Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors. Stahl SM CNS Spectr; 2017 Aug; 22(4):305-311. PubMed ID: 28758887 [TBL] [Abstract][Full Text] [Related]
10. Neurotransmitter interactions in psychotropic drug action: beyond dopamine and serotonin. Greenshaw AJ J Psychiatry Neurosci; 2003 Jul; 28(4):247-50. PubMed ID: 12921219 [No Abstract] [Full Text] [Related]
11. [The problem of reinforcement. From behavioural control to neurochemical background and the development of psychopathologies]. Grigor'ian GA Zh Vyssh Nerv Deiat Im I P Pavlova; 2005; 55(6):747-61. PubMed ID: 16396481 [TBL] [Abstract][Full Text] [Related]
12. Biological markers and the concept of psychiatric illness. Hrdina PD J Psychiatry Neurosci; 1992 Jun; 17(2):41. PubMed ID: 1637799 [No Abstract] [Full Text] [Related]
13. [Cerebral energy metabolism and dysthymia]. Pariante F; Scala A Osp Psichiatr; 1968; 36(3):377-400. PubMed ID: 5733530 [No Abstract] [Full Text] [Related]
14. Brain amines and peptides--their relevance to psychiatry. Smith GC; Copolov D Aust N Z J Psychiatry; 1979 Dec; 13(4):283-91. PubMed ID: 44187 [TBL] [Abstract][Full Text] [Related]
15. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Nikolaus S; Antke C; Müller HW Behav Brain Res; 2009 Dec; 204(1):32-66. PubMed ID: 19523495 [TBL] [Abstract][Full Text] [Related]
16. [Involvement of the dopaminergic system in the mechanisms of immunomodulation]. Al'perina EL Usp Fiziol Nauk; 2014; 45(3):45-56. PubMed ID: 25715636 [TBL] [Abstract][Full Text] [Related]
17. [Monoamine oxidase and its inhibitors. Physiological, physiopathological and pharmacotherapeutic considerations]. Constantinescu I Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1978; 23(4):303-12. PubMed ID: 370952 [No Abstract] [Full Text] [Related]
18. [Biogenic amines (cerebral or cellular localization, influence of various chemical factors)]. Schrammowa H; Rybakowski J Psychiatr Pol; 1972; 6(1):73-9. PubMed ID: 4622259 [No Abstract] [Full Text] [Related]
19. Biogenic amines and psychiatry. Aust N Z J Psychiatry; 1971 Mar; 5(1):4-9. PubMed ID: 4946453 [No Abstract] [Full Text] [Related]
20. [The role of neurotransmitters in psychiatric pathology]. Gherardi D; Fabrizio E; Chirillo S; Garzia P Minerva Psichiatr; 1992; 33(4):247-58. PubMed ID: 1284315 [No Abstract] [Full Text] [Related] [Next] [New Search]